Nuon Therapeutics Inc. Completes $27 Million Series B Financing
The Series B funding will enable Nuon Therapeutics to advance its orally active lead compound, tranilast, through Phase II clinical trials and support the discovery and development of additional compounds. In 2007, [...]
Recent Comments